Phacilitate Leaders World

Sponsors & Exhibitors


MolMed SpA is an Italian Cell&Gene therapy company focused on research, development, manufacturing and clinical validation of innovative therapies in oncology and genetic rare diseases. MolMed built an original dual business model, including a proprietary pipeline in onco-hematology, and a third party service business focused on development and GMP manufacturing of retroviral/lentiviral vector up to 200L batches and ex-vivo transduction of hematopoietic stem cells and T-cells. MolMed owns two of the first GMP facilities authorized in Europe for commercial Cell&Gene therapy products, serving relevant international partners, such as GSK, Orchard, Telethon, Cellectis, Rocket Pharma and undisclosed others. Founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, one of the leading private scientific research institutes in Italy, MolMed is listed on the (MTA) Milan Stock Exchange.

Visit Website
View all Sponsors & Exhibitors
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman